Physician profile
Katherine S Patrick
NPI 1679837058
$2,499.56
in general payments reported to CMS, 2019-2025
22 companies · $288 in 2025
The $288 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $168 · 2021: $305 · 2022: $469 · 2023: $533 · 2024: $477 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $621.60 | 2019-2024 | Jornay Pm |
| Corium, LLC | $295.66 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $220.89 | 2019-2025 | Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $211.06 | 2020-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $209.32 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.64 | 2020-2022 | |
| Sanofi Pasteur INC. | $134.43 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $124.26 | 2023 | Oxlumo |
| Collegium Pharmaceutical, INC. | $71.15 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $62.36 | 2021-2024 | Qelbree |
| Tris Pharma INC | $56.98 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $53.60 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $51.01 | 2022-2024 | Flumist Quadrivalent |
| Neos Therapeutics, Lp | $42.45 | 2019-2020 | |
| Genentech USA, INC. | $39.16 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $26.63 | 2019-2022 | |
| Shire North American Group INC | $25.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.09 | 2024 | Dupixent |
| Abbott Laboratories | $20.98 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.57 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $15.50 | 2025 | Neffy |
| Misonix INC | $14.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.